Physician
Oncology
Dr. Fredrick B. Hagemeister, MD
|
|
Give Review
Doctor Fredrick B. Hagemeister, MD is an expert in the field of Oncology. He attended University of Texas Southwestern Medical School. Fredrick B. Hagemeister is a published doctor. He published 74 publications, including: 'Causes of death in breast cancer: a clinicopathologic study.' Fredrick Hagemeister accepts Medicare payments and is registered with Medicare.gov.
Publications
- Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-Cell lymphoma.
- Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin Lymphoma.
- Patients with mantle Cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone...
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- R-CHOP every 21 days for diffuse large B-Cell lymphoma: still the standard of care?
- Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin...
- Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-Cell lymphoma.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- A phase 2 study of epothilone B Analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas.
- Zoledronic acid for prevention of bone loss in patients receiving primary therapy for Lymphomas: a prospective, randomized controlled phase III trial.
- A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy with Interferon for Advanced Stage Classic Hodgkin's Lymphoma: A 10-Year Follow-up Study.
- Prognostic value of serum CD44, ICAM-1 and VCAM-1 levels in patients with indolent non-Hodgkin Lymphomas.
- Maintenance and consolidation strategies in non-Hodgkin's Lymphoma: A review of the data.
- Incidence and risk factors of venous thromboembolic events in Lymphoma.
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal ly...
- Combination treatment approaches and novel therapies for Lymphoma.
- Follicular dendritic Cell sarcoma: a report of 14 cases and a review of the literature.
- Hodgkin's Lymphoma in younger patients: lessons learned on the road to success.
- Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B Cell...
- Hodgkin transformation of chronic lymphocytic Leukemia: the M. D. Anderson Cancer Center experience.
- Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or Acute lymphoblastic leukemia.
- Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center.
- Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin Lymphoma.
- Immunosuppression and infectious complications in patients with stage IV indolent Lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
- Myelodysplasia and Acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon...
- Lymphoma of the colon.
- Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma.
- Bone marrow involvement in patients with nodular lymphocyte predominant Hodgkin Lymphoma.
- Thalidomide for patients with recurrent Lymphoma.
- Second malignancies after chemotherapy and radiotherapy for Hodgkin Disease.
- Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's Lymphoma.
- Rituximab and chemotherapy for aggressive Lymphomas: a significant advance in therapy.
- NOVP chemotherapy for Hodgkin's Disease transiently induces sperm aneuploidies associated with the major clinical aneuploidy syndromes involving chromosomes X, Y, 18, ...
- Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.
- Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with stage IV indolent Lymphoma.
- An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin Disease.
- European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin di...
- Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relap...
- Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem Cell ...
- Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin''s Lymphoma.
- Phase II trial of denileukin diftitox for relapsed/refractory T-Cell non-Hodgkin lymphoma.
- Stem-Cell transplant for Hodgkin''s lymphoma: does choice of therapy prior to high-dose treatment matter?
- Pentostatin in T-non-Hodgkin''s Lymphomas: efficacy and effect on CD26+ T lymphocytes.
- Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem Cell rescue.
- The role of mitoxantrone in the treatment of indolent Lymphomas.
- Radiotherapy alone for lymphocyte-predominant Hodgkin's Disease.
- Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's Lymphoma and Hodgkin's disease.
- The status of allopurinol in the management of tumor lysis syndrome: a clinical review.
- Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin Lymphoma.
- Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-Cell non-Hodgkin lymphoma.
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin Lymphoma.
- Treatment of the patient with diffuse large B-Cell lymphoma with medical co-morbidities: newer therapies needed.
- Acral necrotizing mycosis fungoides.
- Bendamustine in the treatment of non-Hodgkin''s Lymphomas.
- Burkitt Lymphoma and atypical Burkitt or Burkitt-like Lymphoma: should these be treated as different diseases?
- Eight-year experience with allogeneic stem Cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide...
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-Cell non-Hodgkin lymphoma.
- Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle Cell lymphoma.
- Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's Lymphoma: a review of the evidence.
- Rituximab for the treatment of non-Hodgkin''s Lymphoma and chronic lymphocytic leukaemia.
- Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's Disease patients: significance of mediastinal and non-mediastinal presenta...
- Causes of death in breast Cancer: a clinicopathologic study.
Schools
U Of Tx Southwestern Med Sch At Dallas
Charity Hospital
MD Anderson Tumor Institute
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anal and Rectal Cancer
- Anemia
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas Health Science Center -
University of Texas MD Anderson Cancer Center -
Louisiana State University -
University of Texas Southwestern Medical School
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1073613303 | |
| NPPES Provider LastName | HAGEMEISTER | |
| NPPES Provider FirstName | FREDRICK | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 459.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 33.0 | |
| Percent Opioid Claims | 7.19 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1073613303 |
| Last Name Of The Provider | HAGEMEISTER |
| First Name Of The Provider | FREDRICK |
| View All |
Similar Doctors
|
|
Dr. Jessica P. Hwang, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Nadya Hasham-Jiwa, DO
This Doctor is OpenDoctor Recommended.
|
|
Dr. Putao Cen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph G. Zinner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sewa S. Legha, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gabriel Lopez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Isabella C. Glitza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Donna S. Zhukovsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kanwal P. Raghav, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Srdan Verstovsek, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Pierre Saintigny, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cathy Eng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sadia Saleem, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alexander Wong, MD
This Doctor is OpenDoctor Recommended.
|